Medtronic Q4 EPS $1.62 non-GAAP (+11%); to spin off Diabetes; dividend raised to $0.71

Medtronic plc

Q4 FY25 revenue $8.93B (+5.4% organic); non-GAAP EPS $1.62 (+11% as reported, +16% constant currency).
Plans to spin off Diabetes business into standalone public company within 18 months via IPO/split-off; accretive to margins and EPS.
Dividend raised to $0.71/quarter ($2.84 annual) — 48th consecutive annual increase; payable July 11, 2025.
Sean Salmon departs as EVP Cardiovascular; Skip Kiil promoted to EVP/President Cardiovascular Portfolio; Michael Carter to lead CST.
FY26 guidance: ~5% organic revenue growth; non-GAAP EPS $5.50-$5.60 reflecting tariff uncertainty.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Skip Kiil

EVP and President, Cardiovascular Portfolio

MDT · Medtronic plc

Effective: 2025-05-21
Filed: May 21, 2025, 7:59 PM ET

Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio

Departed

Sean Salmon

EVP and President, Cardiovascular Portfolio

MDT · Medtronic plc

Effective: 2025-05-21
Successor: Skip Kiil
Filed: May 21, 2025, 7:59 PM ET

Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Skip Kiil was appointed as EVP and President, Cardiovascular Portfolio at Medtronic plc.

Action: assuming
Role: EVP and President, Cardiovascular Portfolio

Exact text from the filing

Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sean Salmon departed as EVP and President, Cardiovascular Portfolio at Medtronic plc.

Action: departing
Role: EVP and President, Cardiovascular Portfolio

Exact text from the filing

Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio

View on SEC.gov

Medtronic plc filing history →

Source: SEC EDGAR

accession 0001613103-25-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.